Omnicell, Inc. (NASDAQ:OMCL) Shares Bought by Prudential Financial Inc.

Prudential Financial Inc. grew its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 26.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 231,053 shares of the company’s stock after purchasing an additional 48,193 shares during the quarter. Prudential Financial Inc.’s holdings in Omnicell were worth $10,286,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Intech Investment Management LLC acquired a new stake in Omnicell during the 3rd quarter valued at $753,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Omnicell by 3.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 594,996 shares of the company’s stock valued at $25,942,000 after acquiring an additional 22,198 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Omnicell by 7.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 25,272 shares of the company’s stock worth $1,102,000 after purchasing an additional 1,813 shares in the last quarter. PEAK6 Investments LLC acquired a new position in Omnicell in the 3rd quarter valued at about $448,000. Finally, Martingale Asset Management L P purchased a new position in Omnicell in the 3rd quarter valued at about $507,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Bank of America cut their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Wells Fargo & Company cut their price target on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research report on Monday, March 24th. JPMorgan Chase & Co. reduced their target price on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th. Finally, Benchmark reissued a “buy” rating and issued a $62.00 price target on shares of Omnicell in a research note on Tuesday, February 4th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, Omnicell currently has an average rating of “Hold” and an average price target of $51.00.

Omnicell Price Performance

Shares of Omnicell stock opened at $35.01 on Friday. The business’s fifty day moving average price is $39.01 and its 200 day moving average price is $42.58. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $55.75. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.64 billion, a P/E ratio of 129.67, a PEG ratio of 7.53 and a beta of 0.85.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, research analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.